Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

USA - NASDAQ:NMRA - US6409791000 - Common Stock

2.63 USD
+0.32 (+13.85%)
Last: 10/24/2025, 8:00:01 PM
2.61 USD
-0.02 (-0.76%)
After Hours: 10/24/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NMRA. NMRA was compared to 192 industry peers in the Pharmaceuticals industry. NMRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NMRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NMRA had negative earnings in the past year.
In the past year NMRA has reported a negative cash flow from operations.
In the past 5 years NMRA always reported negative net income.
NMRA had a negative operating cash flow in each of the past 5 years.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of NMRA (-112.63%) is worse than 78.65% of its industry peers.
Looking at the Return On Equity, with a value of -137.84%, NMRA is doing worse than 65.63% of the companies in the same industry.
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

NMRA has more shares outstanding than it did 1 year ago.
NMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

NMRA has an Altman-Z score of -3.26. This is a bad value and indicates that NMRA is not financially healthy and even has some risk of bankruptcy.
NMRA's Altman-Z score of -3.26 is in line compared to the rest of the industry. NMRA outperforms 44.27% of its industry peers.
NMRA has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
NMRA's Debt to Equity ratio of 0.11 is in line compared to the rest of the industry. NMRA outperforms 49.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -3.26
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

NMRA has a Current Ratio of 10.54. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
NMRA has a Current ratio of 10.54. This is amongst the best in the industry. NMRA outperforms 82.81% of its industry peers.
NMRA has a Quick Ratio of 10.54. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.54, NMRA belongs to the top of the industry, outperforming 82.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.54
Quick Ratio 10.54
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

NMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.67%, which is quite impressive.
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NMRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.76% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.67%
EPS Next 2Y15.14%
EPS Next 3Y11.15%
EPS Next 5Y13.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.14%
EPS Next 3Y11.15%

More info and screens

0

5. Dividend

5.1 Amount

NMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (10/24/2025, 8:00:01 PM)

After market: 2.61 -0.02 (-0.76%)

2.63

+0.32 (+13.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners54.6%
Inst Owner Change0.09%
Ins Owners5.41%
Ins Owner Change-0.03%
Market Cap425.93M
Revenue(TTM)N/A
Net Income(TTM)-252089000
Analysts72.86
Price Target7.14 (171.48%)
Short Float %5.77%
Short Ratio7.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.08%
Min EPS beat(2)-10.01%
Max EPS beat(2)12.16%
EPS beat(4)2
Avg EPS beat(4)1.94%
Min EPS beat(4)-13.12%
Max EPS beat(4)18.71%
EPS beat(8)4
Avg EPS beat(8)-27.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.94%
EPS NQ rev (1m)0.16%
EPS NQ rev (3m)6.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS1.13
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.54
Quick Ratio 10.54
Altman-Z -3.26
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
EPS Next Y5.67%
EPS Next 2Y15.14%
EPS Next 3Y11.15%
EPS Next 5Y13.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y12.91%
EBIT Next 5Y7.21%
FCF growth 1Y-62.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.8%
OCF growth 3YN/A
OCF growth 5YN/A

NEUMORA THERAPEUTICS INC / NMRA FAQ

What is the fundamental rating for NMRA stock?

ChartMill assigns a fundamental rating of 2 / 10 to NMRA.


What is the valuation status for NMRA stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUMORA THERAPEUTICS INC (NMRA). This can be considered as Overvalued.


Can you provide the profitability details for NEUMORA THERAPEUTICS INC?

NEUMORA THERAPEUTICS INC (NMRA) has a profitability rating of 0 / 10.


What is the financial health of NEUMORA THERAPEUTICS INC (NMRA) stock?

The financial health rating of NEUMORA THERAPEUTICS INC (NMRA) is 5 / 10.